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Leading Causes of Death U.S.
All other causes: 470943
Pneumonia and influenza: 77,880
COPD: 90,650
Accidents: 89,347
Cancer: 514,657
Cardiovascular: 926,061
Most Cardiovascular Deaths Related to Clotting and Bleeding
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Thrombogenicity of Prosthetic Cardiac Valves
Safety Considerations
Anticoagulant Drugs
 Bleeding
 Allergic Reactions
 Thrombocytopenia
 Skin Necrosis
 Liver Toxicity
 Vascular Reactions
 Rebound Thrombosis
 Anticoagulant Resistance
 Drug Interactions
 Population Variations (gender, age, ethnicity)
Generic Drug
 A generic drug is identical, or bioequivalent to a 
brand name drug in 
 Dosage form 
 Safety 
 Strength 
 Route of administration 
 Quality 
 Performance characteristics
 Intended use
Traditional Generics 
 Similar efficacy is assumed
 Safety is not monitored after introduction 
 Interchangeable
 Economic advantages
 Clinicians thought to have a preference not 
necessarily based on medical literature
 Mandatory changes made by Pharmacy Benefit 
Managers (ie, Blue Cross, Humana, Aetna, etc) 
Genazzani A. Biodrugs. 2007
Declerck P. Drug Safety. 2007
Oral Anticoagulants
 Warfarin (Coumadin®) and its derivatives 
[phenprocoumon (Sintrom®); acenocoumarol 
(Marcumar®)] have been used for over 50 years.
 Generics warfarins available since 1997
 6 generic warfarins FDA rated bioequivalent to 
warfarin:
 Barr Laboratories
 Apothecon
 Genpharm
 Sandoz
 USL Pharm
 Taro Pharmaceuticals
Oral Anticoagulants
 A narrow therapeutic index (range between 
effective and toxic doses)
 Non-linear pharmacokinetics
 Small changes in dose can result in 
considerable changes in the anticoagulant 
response
Key Points Generic Warfarin
 Warfarin has a narrow therapeutic index and a 
varying pharmacodynamic response.
 Close monitoring is needed when patients are 
switched from brand name to generic product, or 
vice versa, or from one generic to another generic 
to avoid under-dosing or over-dosing.
 The generic interchange of warfarin should be 
avoided in elderly patients, and patients with liver 
disease and gastric resection.
 All anticoagulants are critical drugs. In the case of 
warfarin, small changes can result in large 
pharmacodynamic variations.
Biosimilar or Follow-On Biologics
Polysaccharides
Proteins
Glycosylated Proteins
Antibodies
Polynucleotides
Unfractionated Heparin (UFH)
Contaminated 
Unfractionated Heparin
Low Molecular Weight Heparins 
Agent Method of Preparation
Dalteparin Nitrous acid depolymerization
Enoxaparin Benzylation followed by alkaline 
depolymerization
Tinzaparin Enzymatic depolymerization
with heparinase
Pentasaccharide Synthetic analog
VTE Medically-ill
PRIME1 86% UFH (Q8hrs)
Enoxaparin
THE-PRINCE2 19% UFH (Q8hrs)
Enoxaparin
1.4 %
0.2 %
Trial RRR Thromboprophylaxis Patients with VTE (%)
10.4 %
8.4 %
RRR
86%
19%
1Lechler E, et al. Haemostasis 1996;26 Suppl 2:49-56.
2Kleber FX, et al. Am Heart J 2003;145:614-21.
P<0.001 for 
equivalence
P=0.015 for 
equivalence
Low-Molecular-Weight Heparin 
(LMWH)
Clear Benefits over Placebo
MEDENOX1 63% Placebo
Enoxaparin 40mg
PREVENT2 45% Placebo
Dalteparin
ARTEMIS3 47% Placebo
Fondaparinux
Study RRR Thromboprophylaxis Patients with VTE (%)
14.9*
5.5
5.0
2.8
10.5†
5.6
RR
63%
45%
47%
*VTE at day 14; †VTE at day 151Samama MM, et al. N Engl J Med 1999;341:793-800
2 Leizorovicz A, et al. Circulation 2004;110:874-879
3Cohen AT, et al. J Thromb Haemost 2003;1 Suppl 1:P2046
P<0.001
P=0.0015
RRR = relative risk reduction
Major Bleeding
0.00%
0.20%
0.40%
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1.00%
1.20%
1.40%
1.60%
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Medenox Prevent Artemis
LMWH
Placebo
.49%
.16% .2%
1.7%
1.1%
Samama MM, et al. N Engl J Med 1999;341:793-800.
Leizorovicz A, et al. Circulation 2004;110:874-879
Cohen AT, et al. J Thromb Haemost 2003;1 Suppl 1:P2046.
Is VTE Prophylaxis Effective?
Meta-Analysis
Anticoagulant VTE prophylaxis in 19,958 at-risk 
hospitalized medical patients in 9 studies
Dentali F, et al. Ann Intern Med. 2007;146:278-88.
 62% reduction in fatal PE [RR 0.38; CI 0.21-0.69]
 57% reduction in fatal or nonfatal PE [RR 0.43; CI 
0.26-0.71]
 53% reduction in DVT [RR 0.47; CI 0.22-1.00]
 Nonsignificant increase in bleeding [RR 1.32; CI 
0.73-2.37]
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Recurrent VTE
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23%
5% 6%
Recurrent VTE: 1st 24 Hours
Hull RD, et al. Arch Intern Med. 1997;157:2562-2568.
Outcomes UFH
Standard vs Weight-Based Dosing
Outcomes
Standard 
UFH
Weight-based 
UFH P Value
1st aPTT > 1.5* 32% 86% < 0.001
aPTT > 1.5 
in 24 hrs 77% 97% 0.002
aPTT therapeutic 
in 24 hrs 75% 89% 0.08
Minor bleeding 2/52 2/63 1
Major bleeding 1/52 0 0.45
RVTE 8/32 (25%) 2/41 (5%) 0.02
*aPTT > 1.5 times control
Raschke RA, et al. Ann Intern Med. 1993;119:874-881.
Standard and Weight-Based UFH
 Bolus 5000 units then Infusion 1300 units per hour Target aPTT therapeutic range 
of the hospital Check aPTT in 6 hours and 
adjust upward or downward by 
200 units aPTT should be checked every 
6 hours for the first 24 hours 
then Daily or more frequently as 
indicated by the need to 
achieve the therapeutic range Check platelet count baseline 
then every 2 to 3 days from day 
4 thru 14 Initiate warfarin 5 mg on day 1 Continue unfractionated
heparin until the INR is between 
2 and 3 for 2 consecutive days
 Bolus 80 IU/kg then Infusion 18 IU/kg/hr Target aPTT therapeutic range 
of the hospital Check aPTT in 6 hours and 
adjust via the schedule Check platelet count baseline 
then every 2 to 3 days from day 
4 thru 14  Initiate warfarin 5 mg on day 1 Continue unfractionated
heparin until the INR is between 
2 and 3 for 2 consecutive days
Raschke RA, et al. Ann Intern Med. 1993;119:874-881
Kearon C, et al Chest 2008;133:454S-545S
.
Unfractionated Heparin
Subcutaneous Dosing
 FIDO Investigators [1C] Initial Dose 333 U/kg, SC Maintenance 250 U/kg, SC, Q12hrs No monitoring
 Pini Method [1C] 250 u / kg, Q12hrs Adjust dose 6 hours after the AM dose and 
adjust upward or downward based on aPTT of 
1.5 x baseline aPTT
Kearon C, et al JAMA 2006;296:935-942
Kearon C, et al Chest 2008;133:454S-545S
Venographic Assessment
Efficacy and Safety LMWH vs UFH
0.00%
2.00%
4.00%
6.00%
8.00%
10.00%
12.00%
Total VTE DVT PE Major Bld
UFH
Enoxaparin
All patients had bilateral leg venography 
and lung scanning on day 1 and 10. 
No warfarin started until day 11.
%
 P
at
ie
n t
s
Simonneau G, et al. Arch Intern Med. 1993;153:1541-1546. 
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
Total VTE DVT PE Maj Bld
UFH
Dalteparin
%
 P
at
ie
n t
s
Lindmarker P, Holmstrom M. J Intern Med. 1996;240:395-401.
Venographic Assessment
Efficacy and Safety LMWH vs UFH
200 U/kg/Q24hrs
Clinical Outcomes
Efficacy and Safety LMWH vs UFH
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Hull RD, et al. N Engl J Med. 1992;326:975-982.
Tinzaparin 175 U/kg, Q24hrs
0%
1%
1%
2%
2%
3%
3%
4%
4%
RVTE Major Bld
%
 P
at
ie
nt
s
Enoxaparin 1.5 mg/kg, SC, Qday
Merli G, et al. Ann Intern Med. 2001;134:191-202.
Clinical Outcomes
Efficacy and Safety LMWH vs UFH
Enoxaparin 1mg/kg, SC, Q12hrs
UFH
ACCP Guidelines
 Initial treatment with 
LMWH, subcutaneously 
once or twice daily as 
an outpatient [1C] or as 
an inpatient [1A] rather 
than UFH.
 Dalteparin
 200 IU/kg, Qday
 Enoxaparin
 1 mg/kg, Q12hrs or
 1.5 mg/kg, Qday
 Tinzaparin
 175 IU/kg, Qday
 Fondaparinux
 < 50 kg – 5mg, Qday
 50-100 kg – 7.5 mg, Qday
 > 100 kg – 10 mg, Qday
Kearon C, et al Chest 2008;133:454S-545S
Merli GJ. Am J Med. 2008;121:S2-S9
Acute Coronary Syndrome
 5.3 million ER visits due to chest pain
 1.4 million hospitalizations per year 
 15% of (UA/NSTEMI) patients die or have recurrent 
MI within 30 days
 41% of UA/NSTEMI patients die, have a recurrent MI 
or experience severe ischemia requiring 
 Hospitalization within 2 weeks of initial presentation
 85% of patients presenting with UA/NSTEMI go to the 
catheterization laboratory
FRIC
(nadroparin)
FRAXIS
(dalteparin)
ESSENCE
(enoxaparin)
TIMI-11B
(enoxaparin)
0.75 1.00 1.25 1.50
End Point: Death, MI, Recurrent Ischemia / +/- Revascularization
Brunwald E, et al JACC 2002;40:1366-1374
Acute Coronary Syndrome
Efficacy and Safety of Subcutaneous 
Enoxaparin in Non-Q-wave Coronary Events
(ESSENCE)
Enoxaparin
1 mg/kg 
SQ q 12 h
+ ASA
UFH
IV dose-adjusted
+ ASA
Follow-up visit
Day 14
Follow-up visit
Day 14
Follow-up call
Day 30/365
Follow-up call
Day 30/365
Unstable 
angina
Non-Q-wave MI
NSTEMI
Treatment
min 48hrs, max 8 days
Follow-up
N=3,171 Double-blind, multicenter
Cohen M et al. NEJM 1997;337:447-52.
ESSENCE: Results up to 30 days
14 days
Death, MI, 
recurrent angina 19.8% 16.6% 0.019
Death, MI 6.1% 4.9% 0.130
30 days
Death, MI, 
recurrent angina 23.3% 19.8% 0.016
Death, MI 7.7% 6.2% 0.080
Revascularization 32.2% 27.1% 0.001
Endpoints
UFH
(N=1,564)
Enoxaparin 
(N=1,607) p
Cohen M et al. NEJM 1997;337:447-52.
ESSENCE: Results
30 days
Major bleeding 7.0% 6.5% NS
Any bleeding 14.2% 18.4% 0.001
Endpoints
UFH
(N=1,564)
Enoxaparin 
(N=1,607) p
Cohen M et al. NEJM 1997;337:447-52.
ESSENCE: One-year follow-up
Death, MI, recurrent angina
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 UFH (n=332)  Enoxaparin (n=333)
*≥50% platelet count fall from the postoperative peak.
UFH vs Enoxaparin — THR Patients
Warkentin TE et al. Arch Intern Med. 2003;163:2518-2524.
P<0.001
• Secondary analysis of     
665 patients who 
received (UFH) or 
enoxaparin after THR
• The secondary 
analysis employed a 
sensitive laboratory 
definition of HIT that 
allowed for earlier 
diagnosis and treatment
HIT: LMWH vs UFH
1. Warkentin TE. Blood. 2005;106:2600.
2. Martel N et al. Blood. 2005;106:2710-2715.
Study or Subcategory OR (random) 95% CI
Leyvraz 1991
Warkentin 1995†
Ganzer 1999†
Pouplard 1999
Mahlfeld 2002†
Total (95% CI)
*Included surgical patients. †Three studies compared enoxaparin with UFH.
0.001 0.01 0.1 1 10 100 1000
Favors LMWH Favors UFH
Meta-analysis of 5 Studies*1,2
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CURRENT PERSPECTIVE ON 
GENERIC LMWHS
 The regulatory bodies, US FDA and EMEA, may 
allow the generic versions of LMWHs and apply 
the same guidelines as for other biologicals. 
 Additional requirements to provide 
supplementary chemical and biological data to 
support the filing may be needed.  Some 
stipulations from the Citizens Petition may be 
considered.
 Clinical trials may or may not be required for     
specific products for approved indications 
depending upon the filing material review.
Issues with Biosimilars
 Variable potency and response
 Immunogenicty (glycosylation, 
contamination, changes to 3D structure)
 Immune system is able to detect small changes in 
protein structure between an introduced molecule 
versus the original
Is Chemical Characterization of Branded 
LMWH Sufficient to Satisfy Assure 
Pharmacodynamics Equivalence?
 No: LMWHs are hybrid products of biologic 
origin with chemical modifications. The 
starting material is more important to 
characterize for product consistency.
BioSimilar Drugs
 Derived from living cells, therefore they can not 
be copied or duplicated
 Two biologics can result in significantly different 
immune responses
 Lack of scientific evidence to guarantee a safe 
interchange between biologics
 Difficulties exist in: Molecular characterization Depth of knowledge in regard to mechanism of 
action
Genazzani A. Biodrugs. 2007
Declerck P. Drug Safety. 2007
Immunogenicity of BioSimilars
 Generally proteins isolated from human 
tissues or serum are less immunogenic than 
non-human proteins
 Immune system is able to detect small 
changes in protein structure between an 
introduced molecule versus the original
 Methods used to detect formation of 
antibodies:
 Difficulties with measurement
 Inability to compare different studies
Schellekens H. Clin Ther. 2002
Kessler M, et al. Nephrol Dial Transplant. 2006
Immunogenicity of Biosimilars
Clinical Consequences 
 Severe allergic or anaphylactic reaction 
 Immune response to therapeutic protein may reduce 
efficacy
 Immune response leading to autoimmunity to 
patients own endogenous proteins
 Main focus is the questionable efficacy of protein 
and non-protein products that are being 
manufactured
 Manufacturing process in some cases have been 
able to address these concerns
Schellekens H. Clin Ther. 2002
Kessler M, et al. Nephrol Dial Transplant. 2006
Political Statement Scientific Fact
Biosimilar designed to be 
identical to parent product
Biosimilars may be similar but 
not identical
Parent product composition 
varies batch or lot
Batch-to-batch variability is a 
characteristic of all biologics
Variability is unique to each 
product
Limits of acceptable  variability 
defined by clinical experience
Laboratory data predicts 
biosimilar efficacy and safety in 
clinical settings
Laboratory testing not sufficient
Clinical data on efficacy, safety, 
and immunogenicity needed
MFG process changes 
frequently for parent product 
without supporting studies
FDA requires clinical data on 
MFG
MFG changes are supported by 
data
Henry Waxman
Waxman Biosimilars Bill
 Biosimilarity based on chemical, physical, biologic 
and other non-clinical laboratory studies.
 One or more clinical studies are required to 
demonstrate safety, purity and potency.
 Demonstration on similarity in one indication can be 
used to support claims of similarity in other 
indications.
 Requested indications must be approved for the 
reference product.
 Route, dosage and strength must be the same as 
that of the reference product.
Waxman Biosimilars Bill
 Designation of interchangeability is possible, though 
not a requirement for biosimilarity. 
 The official name of the biosimilar agent will be the 
same as that of the reference product.
 Innovator biologic products will receive marketing 
exclusivity for 5 years from the date of approval.
 Period may be extended 6 months if supplement 
application for new indication is approved (excluding 
use in pediatric subpopulation).
 Period may be reduced by 3 months is annual gross 
sales in US exceed $1 billion.
Rep. Anna Eshoo
14th Congressional District of California
Eshoo Biosimilars Bill
 Biosimilarity based on analytical studies to show 
product is highly similar to reference product 
notwithstanding minor differences in clinically 
inactive components.
 Clinical studies are required to demonstrate safety, 
purity and potency in each condition of use 
approved for the reference product.
 Requested indications must be approved for the 
reference product.
 Route, dosage and strength must be the same as 
that of the reference product.
Eshoo Biosimilars Bill
 Designation of interchangeability is possible, 
though not a requirement for biosimilarity.
 The official name of the biosimilar shall be 
unique so that it is distinguished from the 
reference product an any subsequent 
biosimilars.
 Guidance for licensure must be provided by 
the FDA.
FDA has the ability to not approve a given 
product or product class if the current science 
or experience precludes it.
Eshoo Biosimilars Bill
 Innovator biologic products will receive 
marketing exclusivity for 12 years from the 
date of approval.
Period may be extended to 14 years if 
supplement application for new indication is 
approved 
Period may be increased by an additional 6 
months if use in pediatric populations is 
approved.


